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Angiomyolipoma (AML) is a rare benign lipomatous tumour of the liver. It is typically echogenic on
ultrasound, hypodense on computed tomography and hyperintense on magnetic resonance imaging.
Its varied imaging appearance is due to the different proportion of the three cell types which make up
the tumour. This is a case report of a hepatic AML mimicking hepatocellular carcinoma (HCC) with fatty
change in a hepatitis B carrier. Diagnostic difficulty and implications on subsequent management are
discussed in the context of an endemic region for HCC. (Asian J Surg 2002;25(3):251–4)
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Date of acceptance: 23rd April 2002 Figure 1. Ultrasonography revealed a well-defined
echogenic mass in the right lobe of the liver.
INTRODUCTION
Angiomyolipoma (AML) typically occurs in the kidney
and rarely in the liver. Ishak reported the first hepatic AML
in 1976 1 and, since then, there have been about 100
cases reported  in the literature.2,3 With improvements in
imaging, its diagnosis can lead to a conservative approach
to such lesions, as in the kidney. In a region endemic for
hepatocellular carcinoma (HCC), the diagnosis of AML
can be difficult. We report a case of hepatic AML and its
diagnostic implications.
CASE REPORT
A 67-year-old Chinese gentleman, a hepatitis B carrier
with alcoholic liver disease, had a right-sided liver lesion
on ultrasound (US) screening. Clinically, he had
hepatomegaly with the liver 3 cm below the right costal
margin. The α-fetoprotein level was not raised (4.2 μg/L)
and liver function tests were also normal.
On US of the hepatobiliary system, there was a large,
5.0 x 5.5 cm, round echogenic mass in the right lobe of the
liver (Figure 1). The gallbladder contained gallstones and
there were no dilated intrahepatic or extrahepatic ducts.
Dynamic contrast-enhanced computed tomography
(CT) of the liver was then performed, showing a 5-cm mass
in segment VI of the right lobe, which demonstrated
heterogenous enhancement in the arterial phase. There
were irregular central areas of fatty attenuation. The lesion
was less dense in the portal venous phase and, in the
delayed phase, most of the contrast had faded. There was
enhancement of the pseudocapsule and internal septae in
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the portovenous phase (Figure 2). Radiologically, the
lesion was consistent with that of HCC in a hepatitis B
carrier. The kidneys were normal.
The patient underwent cholecystectomy and right
hemihepatectomy with clear surgical margins.
Macroscopically, there was a well-circumscribed, solid,
lobulated, tan-white tumour with scattered yellowish
areas measuring 5 x 5 x 6 cm (Figure 3). The liver was
cirrhotic. Microscopically, the tumour was composed of
sheets of polygonal and spindle-shaped cells with clear to
eosinophilic granular cytoplasm and nuclei ranging from
small and regular to hyperchromatic, multinucleated and
bizarre (Figure 4). Scattered lobules of mature adipocytes,
capillaries and blood vessels with hyalinized to
muscularized walls were also present. The tumour cells
displayed focal positivity for HMB-45 (Figure 5), smooth
muscle actin and desmin.
The patient recovered uneventfully and was discharged
on the sixth postoperative day.
DISCUSSION
AML is a rare benign lipomatous tumour in the liver.
Unlike AML in the kidney, only 5.8% to 10% of hepatic
AML are associated with tuberous sclerosis,2,3 though in
the setting of the latter, the hepatic lesions may represent
Figure 3. Macroscopy revealed a well-circumscribed, tan-
white lobulated tumour with scattered yellowish areas.
Figure 4. On microscopic examination, the liver was
composed of polygonal to spindle-shaped cells with clear to
eosinophilic cytoplasm, adipocytes and blood vessels.(H&E,
original magnification x100)
Figure 5. The tumour cells showed positive staining for
HMB-45. (Streptavidin biotin complex method, original
magnification x200)
Figure 2. The lesion demonstrated enhancement of the
pseudocapsule and internal septae on the portovenous phase of
the enhanced spiral CT. Note the low attenuation areas in the
medial aspect of the mass compatible with presence of fat.
R
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AML and are multicentric.4 The tumour is composed of
three tissue components: blood vessels, smooth muscle
and fat. Extramedullary haemopoiesis is also a distinctive
feature.2
 The unifying factor that aided the histological diagnosis
of AML was the introduction of HMB-45, a human
monoclonal antibody to melanocytes.3 In the past, most
of these tumours may have been misdiagnosed according
to the variants of each cell line. No liver tissue components
or primary liver tumours except AML myoid cells are
reactive to HMB-45.3 The presence of cells expressing
muscle antigens and HMB-45, as well as fat and blood
vessels within the tumour clearly establishes the diagnosis
of AML.
The appearance of hepatic AML on imaging varies
widely because the relative proportion of vessels, muscle
and fat varies widely from tumour to tumour.5 Definitive
preoperative diagnosis is possible and made easier by the
use of US, CT and magnetic resonance imaging (MRI). The
tumour is usually hyperechoic on US, hypodense (less
than –20 Housefield units) on CT and hypervascular on
angiography.2 The fatty component that is crucial for
diagnosis is detected as high signal intensity on MRI.2,6
The fat content of AML varies from less than 10% to
more than 90% of the tumour volume.2 Hence, it can
mimic any other tumour with fatty components. A
diagnostic dilemma arises in tumours with much lower
fatty content. The common differential diagnoses for such
lesions that are hypervascular in an endemic region for
hepatitis B are haemangioma and HCC. Similarly,
malignancies with fatty components, e.g., HCC with fatty
change, are also difficult to differentiate from AML, as
exemplified by this case report. In large HCC with fatty
change, the fatty component is localized and is highly
echogenic on US, and as a low-density area on CT. On the
contrary, small HCC (less than 3.5 cm in diameter has
diffuse fatty change that is harder to differentiate from
benign lipomatous tumours.7
MRI, with its multiplanar visualization and fat
suppression techniques, allows better identification of fat
within the tumour.8 Dynamic CT and MRI have been
suggested as reliable methods for differentiating AML
from HCC and cavernous haemangioma.9–11 From a time
density/intensity study curve, AML shows a marked early
and prolonged enhancement. This is attributed to the
proliferation of blood vessels within the fatty component.
The timing of peak enhancement of AML is intermediate
between HCC, which has a very early peak, and haem-
angioma. The enhancement, which is similar to
haemangioma, is sustained and prolonged, in contrast to
that of HCC. The pattern of enhancement on dynamic
visualization also helps to differentiate these lesions.
Haemangiomatas characteristically demonstrate nodular
enhancement with ”forest-fire“ filling-in effect from the
periphery to the centre, whilst HCCs have pseudocapsular
enhancement. A combination of CT and MRI with their
multi-technique modalities help make a preoperative
diagnosis possible,6,12 and obviates the need for needle
biopsy, which can potentially cause tumour seeding.13
Non-surgical treatment of AML has been advocated
due to its benign nature. This is especially warranted in
patients with poor liver reserves and small lesions in deep-
seated regions of the liver. Nonetheless, in an endemic
region for hepatitis B, one must be cautious about focal
masses in the liver and in advocating a conservative
approach to these lesions.14 Close follow-up is still
necessary and recommended after a definitive diagnosis
of AML.
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